Teva Pharmaceutical Industries Ltd
F:TEV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Teva Pharmaceutical Industries Ltd
F:TEV
|
IL |
|
T
|
Take-Two Interactive Software Inc
XMUN:TKE
|
US |
|
Sibanye Stillwater Ltd
OTC:SBYSF
|
ZA |
|
Banco de Sabadell SA
MAD:SAB
|
ES |
|
Telefonica SA
BMV:TEFN
|
ES |
|
H
|
H & R Block Inc
LSE:0HOB
|
US |
|
S
|
Societe Generale SA
XMUN:SGE
|
FR |
|
Bankinter SA
LSE:0H7O
|
ES |
|
DBV Technologies SA
OTC:DBVTF
|
FR |
|
Q
|
Quest Diagnostics Inc
SWB:QDI
|
US |
|
C
|
Campbell Soup Co
XETRA:CSC
|
US |
|
H
|
Hitachi Ltd
XMUN:HIA1
|
JP |
|
V
|
Vector Group Ltd
SWB:VGR
|
US |
|
Z
|
Ziprecruiter Inc
DUS:47R
|
US |
|
C
|
Commerzbank AG
LSE:0RLW
|
DE |
|
S
|
Swiss Re AG
DUS:SR9
|
CH |
|
Toyota Industries Corp
TSE:6201
|
JP |
|
S
|
Silicon Motion Technology Corp
F:S9M
|
TW |
|
L
|
LifeMD Inc
NASDAQ:LFMD
|
US |
|
S
|
Sumitomo Mitsui Financial Group Inc
XMUN:XMF
|
JP |
|
A
|
Akzo Nobel NV
OTC:AKZOY
|
NL |
|
S
|
Silvercorp Metals Inc
F:S9Y
|
CA |
Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries is a global drug company best known for making generic medicines, which are lower-cost versions of branded drugs after patent protection ends. It also sells a smaller portfolio of branded specialty medicines, with a focus on treatments for the nervous system, breathing problems, and other chronic conditions. Its products are sold to pharmacies, hospitals, doctors, governments, and health systems around the world. Teva makes money mainly by selling finished medicines, either under its own name or through large-volume generic supply contracts. In generics, it competes on cost, manufacturing scale, and the ability to launch approved alternatives quickly when patents expire. In specialty drugs, it earns more from branded therapies that treat specific diseases and often require ongoing prescriptions. What makes Teva important in the drug industry is its role as a major supplier of affordable medicines. It sits between patent-based drug makers and the patients, insurers, and public health systems that need lower-priced alternatives. That mix of high-volume generics and selected branded treatments gives Teva a business model that depends on manufacturing strength, regulatory approvals, and broad distribution rather than a single blockbuster drug.
Teva Pharmaceutical Industries is a global drug company best known for making generic medicines, which are lower-cost versions of branded drugs after patent protection ends. It also sells a smaller portfolio of branded specialty medicines, with a focus on treatments for the nervous system, breathing problems, and other chronic conditions. Its products are sold to pharmacies, hospitals, doctors, governments, and health systems around the world.
Teva makes money mainly by selling finished medicines, either under its own name or through large-volume generic supply contracts. In generics, it competes on cost, manufacturing scale, and the ability to launch approved alternatives quickly when patents expire. In specialty drugs, it earns more from branded therapies that treat specific diseases and often require ongoing prescriptions.
What makes Teva important in the drug industry is its role as a major supplier of affordable medicines. It sits between patent-based drug makers and the patients, insurers, and public health systems that need lower-priced alternatives. That mix of high-volume generics and selected branded treatments gives Teva a business model that depends on manufacturing strength, regulatory approvals, and broad distribution rather than a single blockbuster drug.
Quarter: Teva said Q1 was a solid start to the year, with innovative drugs again doing most of the heavy lifting while generic REVLIMID remained a drag.
Emalex deal: Teva announced its first acquisition under Pivot to Growth, buying Emalex for ecopipam in pediatric Tourette syndrome, and framed it as a high-margin, strategically aligned CNS asset.
Guidance: The company reaffirmed its 2026 outlook on an underlying basis, but updated guidance to reflect roughly $775 million of Emalex-related expenses.
Margin path: Management said the mix shift toward innovative products and ongoing cost savings keep Teva on track for a 30% operating margin in 2027.
Pipeline: Teva highlighted a busy year ahead with 7 milestone readouts, including olanzapine LAI, duvakitug, anti-IL-15, DARI, emrusolmin, and PD-1/IL-2 data.
